EFFECTS OF XENICAL ON LPL AND HTGL FOLLOWING A FAT RICH BREAKFAST

富含脂肪的早餐后赛尼可对 LPL 和 HTGL 的影响

• 批准号: 6245256
• 负责人: Robert H Eckel
• 金额: $ 2.65万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-14 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6245256
• 关键词: clinical research; clinical trials; dietary lipid; drug metabolism; drug screening /evaluation; endocrine disorder chemotherapy; enzyme activity; enzyme inhibitors; human subject; human therapy evaluation; lipoprotein lipase; nutrition related tag; pancreas enzyme; triacylglycerol lipase; weight control agent

Xenical (orlistat) is a new anti-obesity drug which limits fat absorption by the inhibition of pancreatic lipase (PL) activity. Xenical may inhibit systemic plasma lipases as well as gastrointestinal lipases. The effect or lack thereof that Xenical or its metabolites have on lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL) activity during the time triglycerides appear in the circulation after eating needs to be established. Therefore, the effects of Xenical and its metabolites on postprandial pre-and postheparin LPL and HTGL activities and on postprandial plasma lipoprotein concentrations were examined in this clinical trial.

赛尼可（奥利司他）是一种新型减肥药，它能限制脂肪的吸收 通过抑制胰脂肪酶（PL）活性。赛尼可可能抑制 全身性血浆脂肪酶以及胃肠道脂肪酶。效果 或缺乏赛尼可或其代谢物对脂蛋白的影响 脂肪酶（LPL）和肝甘油三酯脂肪酶（HTGL）的活性， 进食后甘油三酯出现在循环中的时间需要 确立了习因此，赛尼可及其代谢产物对 餐后肝素前和肝素后LPL和HTGL活性以及 餐后血浆脂蛋白浓度进行了检查， 临床试验